Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
Rhea-AI Summary
Propanc Biopharma (NASDAQ: PPCB) announced a strategic initiative on Nov 4, 2025 to pursue acquisitions of Digital Asset Treasury (DAT) companies trading below Market Cap to Net Asset Value (MNAV). Management said acquiring undervalued DATs could strengthen Propanc's balance sheet, diversify assets, and create long-term shareholder value while the company continues its oncology development work.
The release cites public data showing Bitcoin treasury companies hold approximately $76.9 billion and Ethereum-based DATs hold about $17.6 billion in digital assets. Propanc's board is evaluating targets and building due diligence frameworks and will update shareholders as qualified targets are identified.
Positive
- Targets undervalued DATs trading below MNAV
- Bitcoin treasury reserves cited at $76.9 billion
- Ethereum-based DAT reserves cited at $17.6 billion
- Strategic aim to strengthen balance sheet and diversify assets
Negative
- None.
News Market Reaction
On the day this news was published, PPCB declined 6.19%, reflecting a notable negative market reaction. Argus tracked a trough of -27.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $15M at that time.
Data tracked by StockTitan Argus on the day of publication.
MELBOURNE, Australia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new treatments for patients suffering from recurrent and metastatic cancer, today announced a strategic initiative to pursue the acquisition of Digital Asset Treasury (DAT) companies that are currently trading below their Market Cap to Net Asset Value (MNAV).
The Company’s management believes that acquiring undervalued DAT entities presents a compelling opportunity to strengthen Propanc’s balance sheet, diversify its asset base, and create long-term shareholder value. These DAT companies typically hold substantial reserves of leading digital assets such as Bitcoin (BTC) and Ethereum (ETH) on their balance sheets.
According to public filings and data compiled by CoinMarketCap.com, the total value held by Bitcoin Treasury companies currently stands at approximately
“We see this as a strategic diversification initiative that can unlock value for Propanc shareholders,” said James Nathanielsz, CEO of Propanc Biopharma. “By identifying DAT companies trading below their intrinsic value, we aim to leverage our public company platform to build a diversified digital asset portfolio while continuing to advance our innovative oncology pipeline.”
Propanc’s board and executive team are currently evaluating potential acquisition targets and developing due diligence frameworks to assess balance sheet strength, digital asset holdings, and operational synergies.
The Company intends to update shareholders as developments progress and qualified targets are identified.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to prevent recurrence and metastasis in cancer patients by targeting and eradicating cancer stem cells through the activation of proenzymes. The Company’s lead product candidate, PRP, is designed to target the root cause of cancer proliferation and spread.
For more information, visit: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
What did Propanc (PPCB) announce on Nov 4, 2025 about acquisitions?
How much digital-asset value did Propanc cite for Bitcoin and Ethereum DATs?
What is Propanc's stated purpose for acquiring DAT companies (PPCB)?
Will Propanc (PPCB) continue its oncology work while pursuing DAT targets?
What steps is Propanc taking to evaluate potential DAT acquisitions (PPCB)?
When will Propanc (PPCB) update shareholders on DAT acquisition progress?
